Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Comprehensive screening of 284 children and adolescents with severe early-onset obesity revealed no pathogenic CARTPT variants; 20 initial variants of uncertain significance across 14 obesity genes were reassessed, but none in CARTPT were upgraded to pathogenic at follow-up (PMID:39462520). Functional assays of the proCART L34F variant demonstrate preserved sorting to the regulated secretory pathway, refuting a missorting mechanism for obesity (PMID:23527253). A separate expression study showed strong correlation between CARTPT and a brain-specific TCF7L2 splice form, suggesting shared neuroendocrine roles but not a direct causal link to inherited obesity (PMID:20033802).
Current evidence yields a limited clinical validity between CARTPT and MONDO:0019182; additional segregation studies and in vivo functional models are needed.
Key take-home: At present, CARTPT variants lack sufficient proof for routine genetic diagnosis of monogenic obesity.
Gene–Disease AssociationLimitedNo CARTPT probands with definitive pathogenic variants identified in 284 screened patients (PMID:39462520) Genetic EvidenceLimitedScreening yielded only variants of uncertain significance in CARTPT without segregation or pathogenic reclassification Functional EvidenceLimitedIn vitro proCART L34F sorting assays are negative for pathogenic effect and expression correlation suggests plausibility but not causality |